Pharmaceutical Polymer Matrices for Controlled Drug Delivery Applications are widely recognized as essential excipients in the advancement of modern drug formulation technology. Identified by CAS {cas_number}, these matrices are characterized by their molecular formula of {molecular_formula} and a molecular weight of {molecular_weight}. Structurally, they are precisely described by the IUPAC name {iupac_name} and can be unambiguously referenced using the InChIKey {inchikey}. Functionally, they fall within the excipient category, serving as delivery platforms for active pharmaceutical ingredients, allowing for tailored release profiles in finished dosage forms.
Examining the physical and chemical properties, the specifics for this polymer matrix include a melting point of {melting_point} and a density of {density}. Other values like boiling point, flash point, or vapor pressure are not supplied here, though such attributes are often central to selection for certain applications. These attributes support its suitability for use in solid oral dosage forms and implantable systems where consistency in performance is essential.
On the regulatory and compliance front, these polymer matrices are registered under REACH, with the status indicated as {ich_json} and further identified by the relevant article number and tonnage band. The product is listed on the TSCA inventory, confirmed with the corresponding section reference {tsca_json}. Relevant ICH guidance, such as ICH Q3C(R8), is applicable and details specific limits for residual solvents as required for excipients of this class. Hazard potential and handling instructions are clarified under GHS, which describes the appropriate hazard statements, signal words, and H-phrases as per {ghs_json}. For quality standards, the product is referenced in official pharmacopeia chapters cited in {pharma_json}. Occupational exposure limits by OSHA (PEL) and NIOSH (REL) are included when available for workplace safety.
In pharmaceutical development, these polymer matrices are chosen for their ability to modulate drug release rates, thus enabling controlled, sustained, or targeted delivery of active pharmaceutical compounds. They are frequently used in matrix tablet formulations and, in some advanced cases, in transdermal and injectable depot systems. The nature of their application is often determined by compatibility with target actives as indexed in PubChem, as well as their ease of processing in established manufacturing routes. While specific drug synthesis routes may vary, these matrices are universally leveraged for compounds where therapeutic consistency over extended durations is imperative.
To meet diverse manufacturing needs, industry-standard packaging options are readily available, including 25 kg drums, 200 kg drums, and intermediate bulk containers (IBCs). Storage recommendations are made in accordance with GHS stability data, typically advising a cool, dry, and well-ventilated area away from direct sunlight or incompatible substances. As is common practice with excipients of this nature, a shelf life of two to five years is generally anticipated when stored under optimal conditions, although exact durations should be verified with each lot’s certificate of analysis.
All source information for this article is drawn from PubChem at https://pubchem.ncbi.nlm.nih.gov/compound/{cid}, the NIST Chemistry WebBook at https://webbook.nist.gov/cgi/cbook.cgi?Name={cas_number}, regulatory details from the ECHA at {echa_url}, and additional chemical inventory status from the EPA TSCA Inventory at https://www.epa.gov/tsca-inventory.
Related Articles
